

VIRTUAL CONFERENCE

Effects of molecular target agent therapy in advanced hepatocellular carcinoma: A multicenter, retrospective study

1 Department of Gastroenterology, Chiba University, Graduate School of Medicine, Chiba, Japan. 2 Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 3 Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan. 4 Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan.

INTRODUCTION

witnessed a Recent years have in systemic remarkable development hepatocellular chemotherapy carcinoma (HCC) [1].

Currently, four molecular target agents (MTA) are available for the treatment of HCC in Japan [2].

Sequential therapy using multiple MTAs is gaining popularity as the gold standard of treatment [3,4].

However, the effect of the treatment strategy transition for HCC remains unclear.

The present study aimed to clarify the current practical use of systemic chemotherapy and its effect on HCC.


AIM

METHOD

- Multicenter, retrospective study.
- 877 patients who underwent MTA therapy for HCC
- From June 2009 to March 2019.
- Patients were classified into three groups according to the period of initial MTA treatment

Period 1: 2009 to 2012 Period 2: 2013 to 2016 Period 3: 2017 to 2019

• Patient characteristics, patterns of MTA use, and prognosis were analyzed among the three groups.



Numb Age (y Sex (r etiolog HB\ HC Alco othe

<u>K. KOBAYASHI</u>, S. OGASAWARA¹, H. UNOZAWA¹, T. IWANAGA¹, N. FUJITA¹, T. SAKUMA¹, H. KANZAKI¹, K. KOROKI¹, S. MARUTA¹, M. NAKAMURA¹, N. KANOGAWA¹, S. KIYONO¹, T. KONDO¹, T. SAITO¹, E. SUZUKI¹, Y. OOKA¹, S. NAKAMOTO¹, A. TAWADA¹, T. CHIBA¹, A. TAKAHASHI², Y. SEKO², M. MORIGUCHI², S. TSUCHIYA³, K. IWAI³, R. SATO³, N. MORIMOTO⁴, T. ARAMAKI³, Y. ITOH², and N. KATO¹.

RESULTS

Table 1. Patients' characteristics

per of patients	877
years) *	70.4 (9.0)
male)	698 (79.6%)
ду	
V	169 (19.3%)
V	399 (45.5%)
ohol	178 (20.3%)
ers	213 (24.3%)
	* Mean (standard deviation)




Table 2. Patients' characteristics according to three periods

	5		
	Phase 1	Phase 2	
Number of patients	267	352	
Age (years) *	68.9 (9.7)	70.2 (8.1)	
Child-Pugh Class			
A	239 (89.5)	306 (86.9)	
others	28 (10.5)	46 (13.1)	
2nd line treatment	3/267 (1.1)	36/347 (10.4)	
Discontinuation due to AE**, All 1st line treatment	85/267 (31.8)	114/346 (32.9)	
Discontinuation due to AE**, Sorafenib for 1st line			
Discontinuation due to AE**, Lenvatinib for 1st line			

use, and the precise transition time.

ILCA2020